Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation.

MLA

Wiesweg, Marcel, et al. “Clinical Response to Crizotinib and Emergence of Resistance in Lung Adenocarcinoma Harboring a MET C-Cbl Binding Site Mutation.” Lung Cancer (Amsterdam, Netherlands), vol. 139, Jan. 2020, pp. 165–68. EBSCOhost, https://doi.org/10.1016/j.lungcan.2019.11.020.

APA

Wiesweg, M., Herold, T., Metzenmacher, M., Eberhardt, W. E., Reis, H., Darwiche, K., Aigner, C., Stuschke, M., Herrmann, K., Nensa, F., Schildhaus, H.-U., & Schuler, M. (2020). Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation. Lung Cancer (Amsterdam, Netherlands), 139, 165–168. https://doi.org/10.1016/j.lungcan.2019.11.020

Chicago

Wiesweg, Marcel, Thomas Herold, Martin Metzenmacher, Wilfried E Eberhardt, Henning Reis, Kaid Darwiche, Clemens Aigner, et al. 2020. “Clinical Response to Crizotinib and Emergence of Resistance in Lung Adenocarcinoma Harboring a MET C-Cbl Binding Site Mutation.” Lung Cancer (Amsterdam, Netherlands) 139 (January): 165–68. doi:10.1016/j.lungcan.2019.11.020.